Cardiac Outcomes of Trastuzumab Therapy in Patients with HER2-positive Breast Cancer and Reduced Left Ventricular ... https://t.co/dOtKNwo3VN
Cardiac Outcomes of Trastuzumab Therapy in Patients with HER2-positive Breast Cancer and Reduced Left Ventricular ... https://t.co/dOtKNwo3VN
RT @md_arianemacedo: Should we keep trastuzumab in an asymptomatic BC pt after an LVEF decline to <50%? Cardiac outcomes of trastuzumab the…
RT @md_arianemacedo: Should we keep trastuzumab in an asymptomatic BC pt after an LVEF decline to <50%? Cardiac outcomes of trastuzumab the…
RT @md_arianemacedo: Should we keep trastuzumab in an asymptomatic BC pt after an LVEF decline to <50%? Cardiac outcomes of trastuzumab the…
【トラスツズマブ治療下で「EF<50%」 [無症候性] のHER2陽性乳癌60例解析:23例でHER継続。うち14例でその後の心イベント認めず。633日 [中央値] 観察後のEFは、継続群と中止群間で有意差なし [54% vs. 56%]】 Breast Cancer Res Treat https://t.co/z5G8bzG7Gc
RT @md_arianemacedo: Should we keep trastuzumab in an asymptomatic BC pt after an LVEF decline to <50%? Cardiac outcomes of trastuzumab the…
RT @md_arianemacedo: Should we keep trastuzumab in an asymptomatic BC pt after an LVEF decline to <50%? Cardiac outcomes of trastuzumab the…
RT @md_arianemacedo: Should we keep trastuzumab in an asymptomatic BC pt after an LVEF decline to <50%? Cardiac outcomes of trastuzumab the…
RT @md_arianemacedo: Should we keep trastuzumab in an asymptomatic BC pt after an LVEF decline to <50%? Cardiac outcomes of trastuzumab the…
Should we keep trastuzumab in an asymptomatic BC pt after an LVEF decline to <50%? Cardiac outcomes of trastuzumab therapy in patients with HER2-positive breast cancer and reduced left ventricular ejection fraction. - PubMed - NCBI https://t.co/BQI2acfu